Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 15, 2009

Allergan Pays Pieris $10M Up Front to Exploit Anticalin Technology in Ophthalmology

  • Allergan is paying Pieris $10 million up front as part of a collaboration focused on exploiting the latter’s Anticalin technology for the development of treatments for serious ocular disorders. 

    Under terms of the deal, which will combine the Anticalin technology with Allergan’s expertise in drug delivery and ophthalmic drug development, the companies will work together both to optimize existing lead Anticalins and design novel candidates. Allergan will have sole responsibility for all discovery, development, regulatory, and commercialization costs. 

    Anticalins are a novel class of biologicals derived from human lipocalins. Pieris’ technology allows the molecules to be isolated from libraries against a range of target classes. The company claims that the molecules are selective and have a high stability, which makes them amenable to depot-formulation strategies. The small size of the molecules, about 20 kDa, means that they can also be produced in micro-organisms.

    Pieris has already built its own pipeline of preclinical Anticalin candidates in a range of disease fields including oncology, infectious diseases, asthma, and ophthalmology.

     



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »